Compare Bumble Inc (BMBL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bumble Inc vs Incyte Corporation — how do they compare? Bumble Inc trades at $2.62 (market cap $366.87M), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 66.9× Bumble Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Bumble Inc nearer its low. Which is the better fit depends on your goals.
| BMBL | INCY | |
|---|---|---|
Market Cap | $366.87M | $24.54B |
Sector | Technology | Health |
52-Week High | $7.17 | $129.93 |
52-Week Low | $2.70 | $81.61 |
Enterprise Value | $672.73M | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bumble (BMBL) trades at $2.59, down 5.13% with bearish technical signals and negative earnings momentum after Q2 2026 missed expectations. The company faces declining revenue and persistent net losses despite a high gross margin of 72.84%. Recent strategic shifts include removing the women-first messaging rule and exploring a potential sale to revive growth amid user engagement challenges.
The outlook remains cautious with significant execution risks from product overhauls and competitive pressures. While valuation ratios like P/S (0.38) and P/B (0.71) appear attractive, profitability concerns and negative cash flow trends offset potential upside. Analyst consensus is mixed with a $3.62 price target but 74% hold ratings reflecting uncertainty.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bumble Inc
Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.
Read more on BMBL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
